Two rare-disease trial wins in one day signal biotech's clinical pipeline is delivering

Amgen reported that its experimental drug dazodalibep hit its target in a late-stage trial for a severe autoimmune disease called systemic Sjögren's, while separately, a drug developed by Ionis and its partner Otsuka met its goal in a trial for a rare inherited form of ALS, the degenerative nerve disease.

Two independent positive results on the same day is not a coincidence to wave away — it reflects years of investment in precision medicine starting to pay off, and it gives both companies a credible path toward regulatory filings that could unlock significant new revenue.

SanDisk's analyst upgrade argues AI has turned memory chips into must-have infrastructure

Rosenblatt initiated coverage of SanDisk with a bullish call, arguing that the explosion of large AI models and the computing work required to run them has transformed NAND memory — the kind of storage in phones and data centers — from a forgettable commodity into a critical bottleneck that companies will pay a premium to secure.

If that framing sticks, SanDisk stops trading like a cyclical chip maker and starts trading like an infrastructure company, which would justify a meaningfully higher valuation than the market has historically given it.

UBS's capital fight with Swiss regulators is a threat to its entire international business model

UBS chief executive Sergio Ermotti went before the Swiss parliament Tuesday to argue against a proposal that would require the bank to hold far more financial cushion behind its overseas operations, calling the rules an insufficient compromise that would damage Switzerland as a global financial hub for decades.

The stakes here go beyond a regulatory technicality — if parliament forces UBS to lock up significantly more capital in its foreign units, the bank's ability to compete globally shrinks, and the rescue-merger that made UBS the dominant Swiss bank starts to look like a liability rather than a triumph.